News
ALT
7.26
+2.11%
0.15
Largest borrow rate increases among liquid names
TipRanks · 2d ago
BUZZ-Viking set to double in 'challenging' year for obesity drug developers
Reuters · 12/31/2024 16:58
Altimmune Could Find A Partner For Its Phase 3 Exercise
Seeking Alpha · 12/30/2024 16:42
Weekly Report: what happened at ALT last week (1223-1227)?
Weekly Report · 12/30/2024 10:36
Most shorted stocks on Wall Street heading into 2025: BYND, KSS, GRPN, and more
Seeking Alpha · 12/27/2024 16:04
Weekly Report: what happened at ALT last week (1216-1220)?
Weekly Report · 12/23/2024 10:41
B.Riley Financial Keeps Their Buy Rating on Altimmune (ALT)
TipRanks · 12/20/2024 18:41
BUZZ-U.S. STOCKS ON THE MOVE-Mission Produce, Sirius XM, Carnival Corp
Reuters · 12/20/2024 15:39
Altimmune call volume above normal and directionally bullish
TipRanks · 12/20/2024 15:25
SHARES OF VIKING THERAPEUTICS UP 4.2%, AMGEN UP 1%
Reuters · 12/20/2024 14:32
Largest borrow rate increases among liquid names
TipRanks · 12/20/2024 13:45
BUZZ-Weight-loss drug developers gain after Novo's obesity drug underperforms in study
Reuters · 12/20/2024 11:40
WEIGHT LOSS DRUG DEVELOPERS RISE PREMARKET AFTER NOVO NORDISK'S OBESITY DRUG CAGRISEMA ACHIEVES LOWER WEIGHT LOSS THAN EXPECTED
Reuters · 12/20/2024 11:03
SHARES OF VIKING THERAPEUTICS UP 9.3%, STRUCTURE THERAPEUTICS UP 3.4%, ALTIMMUNE UP 1.7% PREMARKET
Reuters · 12/20/2024 11:03
Why Altimmune Was Such a Robustly Healthy Stock on Thursday
NASDAQ · 12/19/2024 23:35
BUZZ-U.S. STOCKS ON THE MOVE-Darden Restaurants, Natgas firms, Affirm Holdings
Reuters · 12/19/2024 18:41
Altimmune, Inc. Added to Nasdaq Biotechnology Index Effective December 23, 2024
Barchart · 12/19/2024 16:52
BUZZ-Altimmune up on addition to Nasdaq Biotech index
Reuters · 12/19/2024 13:53
Altimmune set to join Nasdaq Biotechnology index
Seeking Alpha · 12/19/2024 12:38
ALTIMMUNE ADDED TO NASDAQ BIOTECHNOLOGY INDEX
Reuters · 12/19/2024 12:30
More
Webull provides a variety of real-time ALT stock news. You can receive the latest news about Altimmune through multiple platforms. This information may help you make smarter investment decisions.
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for obesity and liver diseases. The Company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and metabolic dysfunction-associated steatohepatitis (MASH). The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. It is also developing HepTcell, an immunotherapeutic product candidate for patients chronically infected with the hepatitis B virus (HBV). The Company has completed the enrollment in its Phase II clinical trial of HepTcell. Its product candidates are based on its proprietary platform technologies, such as EuPort-based Peptide Technology and Synthetic Peptide Technology-Densigen. The Company’s wholly owned subsidiaries include Altimmune, LLC, Altimmune UK, Limited, Spitfire Pharma, LLC and Altimmune AU Pty, Limited.